Tetracycline Hydrochloride Capsules

This product is a broad-spectrum antibacterial agent, with bactericidal effect at high concentrations. This product has certain antibacterial effects on Streptococcus pneumoniae, hemolytic Streptococcus, Streptococcus viridans and some Staphylococci, Clostridium perfringens, Bacillus anthracis, Bacillus plague, Corynebacterium diphtheriae, Clostridium tetani, Brucella, Haemophilus influenzae, Campylobacter, Vibrio cholerae, and also has inhibitory effects on Rickettsia, Mycoplasma, Chlamydia, Spirochete, and some protozoa. Most Enterobacteriaceae such as Escherichia coli, Klebsiella, Salmonella, and Shigella are resistant to this product. This product is better than Gram-positive bacteria for Gram-positive bacteria, but Enterococcus is resistant to it. Others such as Actinomyces, Bacillus anthracis, Listeria monocytogenes, Clostridium, and Nocardia are also sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae and Neisseria meningitidis, but penicillin-resistant gonococci are also resistant to tetracycline. This product has no antibacterial activity against Pseudomonas aeruginosa. It has a certain antibacterial effect on some anaerobic bacteria, but it is far less effective than metronidazole, clindamycin and chloramphenicol, so it is not used clinically. Due to the widespread use of tetracyclines over the years, common clinical pathogens, including Gram-positive bacteria such as Staphylococcus and Gram-negative bacteria such as Enterobacter, are seriously resistant to tetracycline, and there is cross-resistance between similar varieties. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, preventing the binding of aminoacyl-tRNA at this position, thereby inhibiting the growth of peptide linkages and affecting the synthesis of bacterial proteins.

The main ingredient of this product is tetracycline hydrochloride. Its chemical name is 6-methyl-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide hydrochloride.

1. This product is used as the first choice or optional drug for the following diseases. (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. Brucellosis and plague need to be treated with aminoglycosides. 2. Due to the serious resistance of common pathogens to tetracyclines, this type of drug is only indicated when the pathogen is sensitive to this product. This product is also not suitable for the treatment of hemolytic streptococcal infections and any type of staphylococcal infections. 3. This product can be used for patients with tetanus, gas gangrene, yaws, syphilis, gonorrhea, leptospirosis, actinomycetes and Listeria monocytogenes who are allergic to penicillins.

Oral administration, the usual dosage for adults is 0.25-0.5g once, once every 6 hours. The usual dosage for children over 8 years old is 25-50mg/kg per day, taken in 4 divided doses. The course of treatment is generally 7-14 days, while mycoplasma pneumonia and brucellosis require about 3 weeks.

1. Digestive system: Gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort, abdominal distension, diarrhea, and occasionally pancreatitis. Occasionally, there are reports of esophagitis and esophageal ulcers, which mostly occur in patients who go to bed immediately after taking the medicine. 2. Hepatotoxicity: Usually fatty liver degeneration, which is prone to occur in pregnant women and patients with original renal impairment, and can also occur in patients without the above conditions. Pancreatitis caused by this product can also occur simultaneously with hepatotoxicity, and the patient does not have primary liver disease. 3. Allergic reactions: Mostly maculopapular rash and erythema, in addition to urticaria, angioneurotic edema, allergic purpura, pericarditis, and aggravation of systemic lupus erythematosus skin lesions can be seen, and epidermal exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur. Some patients using this product may have photosensitivity when exposed to the sun. Therefore, it is recommended that patients should not be exposed directly to sunlight or ultraviolet rays, and the drug should be stopped immediately if erythema appears on the skin. 4. Blood system: Occasionally may cause hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia. 5. Central nervous system: Occasionally may cause benign intracranial hypertension, which may manifest as headache, vomiting, papilledema, etc. 6. Nephrotoxicity: Patients with significant renal impairment may develop azotemia, hyperphosphatemia and acidosis. 7. Superinfection: Long-term use of this product may induce superinfection caused by drug-resistant Staphylococcus aureus, Gram-negative bacilli and fungi, and in severe cases may cause sepsis. 8. The use of this product can reduce the normal flora in the human body, leading to vitamin deficiency, fungal reproduction, dry mouth, pharyngitis, angular cheilitis, glossitis, etc.

It is contraindicated for patients who are allergic to tetracyclines.

Precautions for children: When using this product during tooth development (mid- and late-stage pregnancy, infants and children under 8 years old), tetracycline can form stable calcium compounds in any bone tissue, leading to yellowing of permanent teeth, enamel hypoplasia and bone growth inhibition, so this product should not be used in children under 8 years old. Precautions for pregnancy and lactation: This product can enter the fetus through the placental barrier and deposit in the calcium area of teeth and bones, causing fetal tooth discoloration, poor enamel regeneration and inhibition of fetal bone growth. This type of drug has teratogenic effects in animal experiments, so it should not be used by pregnant women. Pregnant women are particularly sensitive to the hepatotoxic reaction of tetracycline and should avoid using this type of drug. This product can be secreted from breast milk, and the concentration in breast milk is high. It has the potential to cause serious adverse reactions to infants. When using it, breastfeeding women should suspend breastfeeding. Precautions for the elderly: Elderly patients are often accompanied by renal impairment, so the dosage needs to be adjusted. The use of this product is prone to cause hepatotoxicity, so elderly patients should use it with caution.

1. When used with antacids such as sodium bicarbonate, the absorption of this product will be reduced and its activity will be reduced due to the increase in the pH value in the stomach. Therefore, antacids should not be taken within 1 to 3 hours after taking this product. 2. Drugs containing metal ions such as calcium, magnesium, and iron can form insoluble complexes with this product, reducing the absorption of this product after oral administration. 3. When used in combination with the general anesthetic methoxyflurane, its nephrotoxicity can be enhanced. 4. When used in combination with strong diuretics such as furosemide, renal damage can be aggravated. 5. When used in combination with other hepatotoxic drugs (such as anti-tumor chemotherapy drugs), liver damage can be aggravated. 6. The lipid-lowering drugs colestyramine or colestipol can affect the absorption of this product, and must be taken several hours apart. 7. This product can reduce the effect of contraceptives and increase the possibility of extramenstrual bleeding. 8. This product can inhibit the activity of plasma prothrombin, so patients receiving anticoagulant therapy need to adjust the dose of anticoagulants.

Keep away from light, sealed and stored in a dry place.

0.25g

24 months

Hebei Yineng Pu Pharmaceutical Co., Ltd.

• Founded in:

  2003-09-04

• Address:

  No. 1 Yinengpu Avenue, Zhuolu County

• Tax NO.:

  91130731754015073N

• Registered Funds:

  20 million yuan

• Email:

  Log in to view